Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
Type:
Grant
Filed:
August 18, 2005
Date of Patent:
August 3, 2010
Assignee:
Panion & BF Biotech, Inc.
Inventors:
David W. K. Kwok, Nikolay Mintchev Stoynov
Abstract: A sustained release, solid pharmaceutical preparation for oral use in a daily dosage regimen is provided, which comprises at least one sparingly soluble main drug, such as an erythromycin derivative. The pharmaceutical preparation comprises the main drug(s), a water-soluble alginate salt and an organic carboxylic acid. In particular, a controlled release tablets of clarithromycin is provided.
Type:
Application
Filed:
May 18, 2004
Publication date:
November 24, 2005
Applicant:
Panion & BF Biotech Inc.
Inventors:
Yih Hsiao, Te Liu, Ming Lin, Ling Hsiao, Chung-Ming Chiang
Abstract: The present invention relates to pharmaceutical-grade ferric citrate. Pharmaceutical-grade ferric citrate contains a definite composition and a definite hydrate. The present invention also relates to a method using a solid—solid reaction to produce pharmaceutical-grade ferric citrate. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of pharmaceutical-grade ferric citrate and a food comprising pharmaceutical-grade ferric citrate.